Overview
- A federal securities complaint accuses Erasca and its CEO and CFO of violating Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 by making false or misleading statements about ERAS-0015.
- The filings say Erasca touted ERAS-0015 as a potential "best‑in‑class" therapy and presented preclinical data that relied on improper comparisons to Revolution Medicines’ RMC-6236.
- The complaint alleges those comparisons lacked a reasonable basis and created undisclosed exposure to patent infringement and trade‑secret claims from Revolution Medicines.
- Several plaintiff firms issued investor notices on Monday and have set August 10, 2026 as the deadline to move for appointment as lead plaintiff; no class has been certified and investors are not represented unless they retain counsel.
- The suits contend that once the alleged problems were disclosed investors suffered losses and may seek recovery on a contingency‑fee basis, with the lead plaintiff expected to direct the litigation if the court appoints one.